Healthcare - Biotechnology - NASDAQ - US
$ 1.18
-5.6 %
$ 63.8 M
Market Cap
3.47
P/E
INCOME STATEMENT
96.7 M
REVENUE
21.5 M
OPERATING INCOME
22.8 M
NET INCOME
EFFICIENCY
Earnings Waterfall
Spero Therapeutics, Inc.
| Revenue | 96.7 M |
| Cost Of Revenue | 367 K |
| Gross Profit | 96.4 M |
| Operating Expenses | 75.3 M |
| Operating Income | 21.5 M |
| Other Expenses | -1.32 M |
| Net Income | 22.8 M |
Income Statement
Millions
| Dec-2023 | Dec-2022 | Dec-2021 | Dec-2020 | Dec-2019 | Dec-2018 | Dec-2017 | Dec-2016 | Dec-2015 | |
|---|---|---|---|---|---|---|---|---|---|
| REVENUE | |||||||||
| Revenue | 96.7 | 48.6 | 18.3 | 9.3 | 4.7 | 4.0 | 2.0 | 0.3 | 0 |
| GROSS PROFIT | |||||||||
| Cost Of Revenue | 0.4 | 1.5 | 1.1 | 67.0 | 65.8 | 33.9 | 32.9 | 26.3 | 11 K |
| Gross Profit | 96.4 | 47.0 | 17.1 | (57.7) | (61.0) | (29.9) | (30.9) | (26.0) | 11 K |
| OPERATING INCOME | |||||||||
| Operating Expenses | 75.3 | 79.1 | 106.2 | 88.4 | 68.0 | 42.8 | 41.7 | 33.6 | 13.3 |
| Selling, General and Administrative Expenses | 25.6 | 36.5 | 41.7 | 21.4 | 15.6 | 12.9 | 10.8 | 7.2 | 2.2 |
| Research and Development Expenses | 51.4 | 47.6 | 64.5 | 67.0 | 65.8 | 33.9 | 32.9 | 26.3 | 11.1 |
| Operating Income | 21.5 | (42.2) | (88.0) | (79.1) | (63.2) | (42.8) | (41.7) | (33.2) | (13.3) |
| PRE-TAX INCOME | |||||||||
| Interest Income Expense | 0 | 2.6 | 1.9 | 0 | 0 | 0.3 | 0.3 | 0 | 0 |
| Total Other Income | 3.9 | (4.2) | (1.8) | 0.8 | 2.3 | 1.1 | 1.8 | 0.6 | 0.2 |
| Pre-Tax Income | 25.4 | (46.4) | (89.8) | (78.3) | (60.9) | (41.7) | (46.1) | (32.6) | (13.2) |
| NET INCOME | |||||||||
| Tax Provision | 2.6 | 1.6 | 1.5 | (0.8) | (0.8) | 1.1 | (0.4) | (7.7) | (3.2) |
| Net Income | 22.8 | (48.0) | (91.3) | (77.5) | (60.2) | (41.7) | (46.1) | (25.5) | (10.2) |
| EPS | 0.43 | 1.28 | 2.96 | 3.46 | 3.31 | 2.6 | 17.8 | 3.86 | 1.54 |